Panama and Guatemala Compared: Central America Six-Country Device Rules

1. Key takeaways

Panama and Guatemala are both in Central America, but device regulation there consists of two separate systems that cannot be substituted for one another. In Panama, the authority is DNDM within MINSA under Article 3 of Ley 90; risk is graded A, B, C and D under Article 30 of DE 490 following the latest GHTF and IMDRF rules, with the higher class applying where a product meets two; the working credential is the technical standard certificate (CCT), valid five years, free and mandatory for public procurement under Article 21 of DE 490, while the start of sanitary registration remains with the health authority under Article 18 of Ley 92; devices are exempt from import duty under Article 28 of Ley 90; and vigilance includes a 72-hour serious adverse event report under Article 56 of DE 490.

In Guatemala, the authority is DRCPFA under MSPAS and above it DGRVCS; classification has four categories, I to IV, built on the axis of use combined with sterility under Annex 1 of NT-37; the credential is the Inscripción Sanitaria, valid five years, after which a fresh application under Article 5 of NT-37 is required rather than a renewal; the registrant must be a domestic establishment holding a Licencia Sanitaria; and the current technical standards set no device vigilance reporting deadline.

Both countries are in transition: Panama through WTO notification PAN/135 of 8 December 2025, Guatemala through GTM/106, notified on 11 February 2026, proposed to take effect on 1 December 2026 and to repeal Government Agreement 712-99. Costa Rica, Nicaragua, Honduras and El Salvador await verification in their own volumes and are not inferred here.

2. Legal basis

The comparison below is organised by function rather than by instrument, so that equivalent provisions can be read side by side. Each row carries the source for both jurisdictions, because the two systems reach comparable outcomes by different legal techniques.

3. Expert insights

Insight 1: the classification axes differ, so class numbers cannot be converted. Article 30 of the Panamanian decree is a risk-based A to D system following the latest GHTF and IMDRF rules, with the higher class prevailing. Annex 1 of NT-37 builds four categories from the axis of use and sterility. A product classified as B in Panama may carry a different class in Guatemala, with no conversion formula. Copying one class into the other’s form is the most common technical error in multi-country projects.

Insight 2: the credentials differ in legal character. The CCT is a transitional credential valid five years, free and mandatory for public procurement, while the start of the final sanitary registration remains with the health authority under Article 18 of Ley 92. The Inscripción Sanitaria is a final registration valid five years, but Article 9 of NT-37 provides that expiry does not lead to renewal and that a fresh application under Article 5 is needed. The two five-year periods differ in meaning, and lapse is heavier in Guatemala.

Insight 3: the vigilance gap is the widest, and neither model can be transplanted. Article 56 of DE 490 sets a 72-hour deadline for serious adverse events, with the six criteria in Article 49 as the gate. Guatemalan standards set no device reporting deadline and place vigilance on the pharmaceutical side under NT 19-2009. Following the Guatemalan habit in Panama would commit a minor offence under Article 35.2 of Ley 90, while applying the Panamanian 72 hours in Guatemala would create an obligation that does not exist.

Insight 4: both countries are in transition, but convergence is not a six-country registration. PAN/135 and GTM/106 entered the WTO process in late 2025 and early 2026, showing that the main markets are rebuilding device rules simultaneously. Each text is notified, approved and brought into force separately, with no mutual recognition. Companies cannot defer an application in either market on that basis, nor assume that approval in one carries into the other.

4. Practical recommendations

• Manage the two classification outcomes separately. Give Panama (A to D) and Guatemala (I to IV) independent fields in the product master data and prohibit reuse across markets.
• Plan renewals against each credential cycle. Panama follows the five-year CCT and licence renewal 60 working days before expiry; Guatemala follows the five-year registration, which must be completed before expiry because a lapse means a full new application.
• Build the vigilance system to the stricter market. Use the Panamanian 72 hours as the baseline for classification and escalation procedures, and apply current Guatemalan requirements there while tracking the implementation of GTM/106.
• Do not suspend applications because a new generation of rules is coming. The proposed adoption date of PAN/135 is pending and GTM/106 is proposed to take effect on 2026-12-01; until an approved text appears, the current rules apply in both countries.
• Leave the other four countries to their own volumes. The authorities, classifications and credentials of Costa Rica, Nicaragua, Honduras and El Salvador must be verified in their own volumes rather than inferred here, which avoids contaminating the comparison.

5. Verification checklist

• □ Panama classification assigned as A, B, C or D under Article 30 of DE 490, with the higher-class rule recorded
• □ Guatemala classification assigned independently under Annex 1 of NT-37, with no reuse of Panamanian class numbers
• □ CCT and Inscripción Sanitaria managed separately, with names not interchanged
• □ Five-year CCT and licence renewal 60 working days before expiry scheduled for Panama
• □ Guatemalan renewal scheduled before the five-year expiry, with the re-application consequence flagged
• □ Vigilance procedure built on the Panamanian 72-hour baseline and not applied to Guatemala
• □ Remaining four countries marked as awaiting verification, with no inference made
• □ Status of PAN/135 and GTM/106 recorded, with current applications still running

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Panamanian market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com